AI generated summary of Pubmed citation/abstract with PMID 38093497

https://pubmed.ncbi.nlm.nih.gov/38093497
This review focuses on the potential of new targets for immunotherapy in treating small cell lung cancer (SCLC), a highly aggressive malignancy with limited treatment options. Current first-line treatment with carboplatin or cisplatin plus etoposide chemotherapy offers only a 10-month survival rate, and most patients relapse within a few months. While immunotherapy has shown progress in treating SCLC patients, the benefits have been limited, with current immune checkpoint inhibitors PD-1/PD-L1 and CTLA-4 providing minimal survival improvements. The review explores four new targets (DLL3, TIGIT, LAG-3, and GD2) that could play a role in SCLC immunotherapy, aiming to find strategies to improve outcomes for SCLC patients.